ArticleAnnals of surgical oncology2026
Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited treatment options. Charged multivesicular body protein 3 (CHMP3), a core component of ESCRT-III, is involved in membrane remodeling. However, its clinical and biological relevance in PDAC remained unclear. This study evaluated the prognostic association and functional relevance of CHMP3 in PDAC. PATIENTS AND
methodsCHMP3 expression and clinical outcomes were analyzed using TCGA and CPTAC3 datasets. Protein expression was assessed by immunohistochemistry in a retrospective cohort of resected PDAC. Additional prognostic information was evaluated using concordance indices. Functional analyses were performed using siRNA-mediated CHMP3 knockdown in MIAPaCa-2 and PANC-1 cells. Single-cell RNA sequencing data assessed cell type-specific expression.
resultsCHMP3 expression was elevated in PDAC and associated with worse overall and disease-free survival in the TCGA and IHC cohorts. In the immunohistochemical cohort, higher CHMP3 expression was associated with poorer outcomes and modestly improved clinicopathologic prediction models. However, CHMP3-high status was substantially imbalanced with nonreceipt of adjuvant chemotherapy, limiting separation of CHMP3-related prognostic effects from treatment-related confounding. In vitro, CHMP3 knockdown suppressed cell proliferation, colony formation, and migration, and increased gemcitabine sensitivity. Single-cell RNA-seq showed CHMP3 enrichment in tumor epithelial and stromal/CAF populations relative to immune cells.
conclusionsCHMP3 expression is associated with poor outcomes in PDAC and may provide modest additional prognostic information when combined with conventional factors, although residual confounding by adjuvant therapy cannot be excluded. These findings support the biological relevance of CHMP3 and suggest that CHMP3 may represent a prognosis-associated marker requiring external validation.
Indexed as
Identifiers
42552496What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.